Financials in USD. Standardized financial statements.
A compact view of how Santen Pharmaceutical Co., Ltd. turns revenue into operating income and net income.
| Metric | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $309.21B | $300.00B | $301.96B | $279.04B | $266.26B | $249.60B | $241.56B | $234.03B | $224.94B | $199.10B |
| Revenue Growth? | +3.1% | -0.6% | +8.2% | +4.8% | +6.7% | +3.3% | +3.2% | +4.0% | +13.0% | 0.0% |
| Cost of Revenue? | $138.53B | $128.98B | $123.26B | $112.95B | $109.67B | $98.22B | $94.83B | $90.76B | $86.38B | $74.97B |
| Gross Profit? | $170.68B | $171.03B | $178.71B | $166.09B | $156.59B | $151.38B | $146.72B | $143.26B | $138.56B | $124.13B |
| Gross Margin? | +55.2% | +57.0% | +59.2% | +59.5% | +58.8% | +60.6% | +60.7% | +61.2% | +61.6% | +62.3% |
| Operating Expenses? | $122.74B | $124.15B | $140.17B | $169.18B | $120.70B | $138.47B | $113.19B | $98.16B | $99.87B | $91.65B |
| Operating Income? | $47.94B | $46.88B | $38.54B | -$3.09B | $35.89B | $37.80B | $33.53B | $45.10B | $38.69B | $32.48B |
| EBITDA? | $67.41B | $59.01B | $50.72B | $12.95B | $52.93B | $70.28B | $51.06B | $56.97B | $49.70B | $42.79B |
| Income Before Tax | $50.30B | $47.48B | $29.87B | -$5.80B | $35.62B | $12.42B | $32.09B | $43.12B | $39.26B | $31.82B |
| Income Tax Expense | $10.48B | $11.63B | $3.17B | $9.18B | $8.43B | $5.77B | $10.38B | $11.17B | $4.00B | $8.77B |
| Net Income? | $39.62B | $36.26B | $26.64B | -$14.95B | $27.22B | $6.83B | $23.62B | $31.95B | $35.26B | $21.72B |
| EPS? | $121.43 | $103.98 | $72.62 | $-38.58 | $68.07 | $17.10 | $59.16 | $78.67 | $86.76 | $52.96 |
| Diluted EPS? | $121.43 | $103.68 | $72.37 | $-38.58 | $67.97 | $17.06 | $59.01 | $78.43 | $86.45 | $52.76 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality